Fig. 6: FasL treatment of CD34+ HSPCs increase their stemness. | Bone Marrow Transplantation

Fig. 6: FasL treatment of CD34+ HSPCs increase their stemness.

From: Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo

Fig. 6

a, b FasL treatment enhances HSPCs stemness demonstrating higher F510/F580 fluorescence ratio (FR) correlated with Glutathione (GSH) level. (a) Representative flow cytometry histogram (b) results of 3 independent experiments of MPBCs treatment with 100 ng/ml of FasL; Mean ± SEM *P ≤ 0.05; Paired T-test. c–i 7 Days expansion capacity after short (5 min, 1 h and 4 h) exposure of purified CD34+ cells with 100 ng/ml FasL. (c) Percentage of CD34+ cells per total cell population, (d) total cell number per well, (e–i) percentage of HSPCs subpopulations per total CD34+ population: (e) Self-renewal HSCs (CD34+CD38neg/lowCD90+CD45RA−), (f) MPP (CD34+CD38neg/low CD90−CD45RA−), (g) LMPP (CD38Neg/LowCD90−CD45RA+), (h) OPP (CD38+high), (i) early-stage MkPs (CD38Neg/lowCD41a+), (c–h): N = 3, (i) N = 2, Mean ± SEM, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 Paired T-test.

Back to article page